Genmab — December 2019
-
-
Jep, Jans begejstring og selvtillid fejler ikke noget. ""Vores program er hundrede gange mere potent end stoffet fra Regeneron og to til fire gange mere potent end det bedste program fra Roche. Der er overvældende interesse fra hele verden for at få adgang til det program."
-
-
Forty Seven also got a boost, as positive data from its first-in-class candidate against its namesake target- CD47- helped add 80% to the company's market cap. The data add an important proof of concept to the hypothesis of unmasking the so-called 'don't eat me' signal from cancer cells to drive their destruction by macrophages- a fundamental part of the company's foundational technology.
-
But Bernstein's Ronny Gal was pessimistic over the progress of the antibodies in multiple myeloma (MM), noting that the levels of cytokine release syndrome (CRS) management required for both CC-93269 and REGN5458 could mean that the modality "is not categorically safer than CAR-T," potentially limiting its uptake into earlier lines of therapy.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind